ADDvise Group has entered into a share purchase agreement with the owners of Labplan Ltd. (“Labplan”) regarding the acquisition of all shares of Labplan. Closing takes place today.
Labplan, based in Kildare, Ireland, is a distributor of specialized advanced instruments, consumables and service to the life science and biopharmaceutical industry. The company serves large multi-national pharma companies as well as government-backed research institutions in Ireland and Northern Ireland.
Labplan’s revenue for the last twelve months per October 31, 2023, amounted to EUR 16.9 million, with an adjusted EBITDA of EUR 3.9 million, corresponding to an adjusted EBITDA margin of 23.0 percent.
The acquisition will be consummated at an initial cash consideration of EUR 13.3 million, and performance-based payments expected to amount to EUR 7.2 million in aggregate over a two-year period.
The acquisition is financed through own funds. ADDvise assesses that the acquisition will have a positive impact on ADDvise’s earnings per share during the financial year 2024.
Mangold Fondkommission AB acted as financial adviser to ADDvise in connection with the acquisition.
This information is information that ADDvise Group AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on December 22, 2023 at 17:40 CET.
About ADDvise Group
ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Premier Growth Market and Mangold Fondkommission AB is the Company’s Certified Adviser. Additional information is available at www.addvisegroup.com.